QNCX Stock Overview A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Quince Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Quince Therapeutics Historical stock prices Current Share Price US$1.76 52 Week High US$2.45 52 Week Low US$0.51 Beta 0.63 1 Month Change -10.20% 3 Month Change 133.11% 1 Year Change 55.75% 3 Year Change -85.93% 5 Year Change -96.86% Change since IPO -94.65%
Recent News & Updates
Quince Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 20 Quince Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 19
New minor risk - Shareholder dilution Nov 14
Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting Nov 12
New minor risk - Profitability Nov 08
CEO, Chief Medical Officer & Director recently bought US$107k worth of stock Sep 04 See more updates
Quince Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 20 Quince Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Dec 19
New minor risk - Shareholder dilution Nov 14
Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting Nov 12
New minor risk - Profitability Nov 08
CEO, Chief Medical Officer & Director recently bought US$107k worth of stock Sep 04
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex Aug 20
Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T) Aug 15 Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024 Aug 14
Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Jun 23
Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System Jun 05
Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 26
Quince Therapeutics, Inc. Launches Scientific Advisory Board Feb 22
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors Feb 15
CEO & Director exercised options to buy US$336k worth of stock. Jan 18
Independent Chairman of the board recently bought US$58k worth of stock Dec 10
Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Dec 09
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer Oct 29
Insufficient new directors Oct 29
New minor risk - Shareholder dilution Oct 27
Quince Therapeutics, Inc. Appoints Luca Benatti as Director Oct 26 Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million. Oct 24
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex Sep 29
Quince Therapeutics Appoints Charles S. Ryan as President Sep 07
Independent Chairman of the board recently bought US$108k worth of stock Sep 03
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023 Aug 12
CEO, President & Director recently bought US$99k worth of stock Aug 10
New minor risk - Share price stability Jul 25 Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million. Jul 25
Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million. May 05
Price target increased by 56% to US$12.00 Feb 17
Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement Dec 17
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation Nov 21
Insufficient new directors Nov 16
Insufficient new directors Oct 11
Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures Aug 31
Price target increased to US$8.38 Aug 05
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 Jul 28
Cortexyme to change name and ticker symbol next month Jul 27
Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022 Jul 24 Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index
Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections Jun 22
Cortexyme, Inc. Appoints June Bray to its Board of Directors Jun 14 Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million. Dr. Dirk Thye and Philip Low to Join Cortexyme Board
Price target decreased to US$7.60 Apr 27 Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588 Mar 10
Price target decreased to US$7.60 Mar 10
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment Mar 01 Cortexyme, Inc. Announces Executives Changes Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application
Price target increased to US$44.00 Jan 27
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors Dec 15
We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate Dec 15
COO, CFO & Treasurer exercised options to buy US$387k worth of stock. Nov 19
Cortexyme: A Challenging Path Forward Nov 17
Cortexyme: Positive Lessons To Be Learned From Disappointing Results Nov 01
Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease Oct 11
COO, CFO & Treasurer exercised options and sold US$217k worth of stock Oct 09
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021 Sep 29
Cortexyme: Alzheimer's Readout In November A Binary Event Sep 12
Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 Sep 09
Price target increased to US$97.71 Aug 26
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit Aug 26
We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth Aug 23
Price target increased to US$89.00 Aug 09
Price target increased to US$78.29 Jul 28
Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 Jul 23
COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock Jul 01 Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index
Independent Director Kevin Young has left the company Jun 22 Shareholder Returns QNCX US Biotechs US Market 7D -7.9% -3.8% -2.7% 1Y 55.8% -2.6% 23.4%
See full shareholder returns
Return vs Market: QNCX exceeded the US Market which returned 23.4% over the past year.
Price Volatility Is QNCX's price volatile compared to industry and market? QNCX volatility QNCX Average Weekly Movement 18.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: QNCX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QNCX's weekly volatility has increased from 12% to 19% over the past year.
About the Company Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
Show more Quince Therapeutics, Inc. Fundamentals Summary How do Quince Therapeutics's earnings and revenue compare to its market cap? QNCX fundamental statistics Market cap US$78.32m Earnings (TTM ) -US$53.26m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) QNCX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$53.26m Earnings -US$53.26m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.21 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 33.2%
How did QNCX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 22:22 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Quince Therapeutics, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Kumaraguru Raja Brookline Capital Markets Sumant Satchidanand Kulkarni Canaccord Genuity
Show 7 more analysts 
